KPMG – China Life Sciences Sector Overview and Outlook, Apr 2025

The main theme of the report is the analysis of the life sciences sector in China, including an overview of current trends and future outlook.

Key findings include a decrease in deal activity in 2020 due to economic uncertainty from the pandemic, a significant increase in 2021 driven by investor interest in healthcare innovations, and a decline from 2022 due to inflation, rising interest rates, and geopolitical tensions. Post-2024, deal activity in China is expected to grow with government support and reforms. Increased innovation and R&D efforts will drive strategic partnerships and cross-border deals. An aging population will boost demand for healthcare solutions, leading to more deals related to age-related diseases.